Caribou Biosciences

Caribou Biosciences is an operator of a medical technology company intended to analyze cell and genome engineering. The company specializes in cellular engineering and analysis based on the CRISPR-Cas9 technology platform which paired with a guide RNA, cuts double-stranded DNA and allows for specific changes to DNA, enabling the development of therapeutics for agricultural biotechnology, industrial biotechnology, and basic and applied biological research.

Caribou Biosciences, established in 2011 and headquartered in United States, North America., specializes in Early Stage Venture investments across Biotechnology, Health Care, Medical, Therapeutics, Genetics, Pharmaceutical, Precision Medicine, Venture Capital. The organization boasts a portfolio of 1 investments, with an average round size of $15.0M and 1 successful exits. Their recent investments include Intellia Therapeutics, Novartis, Atlas Venture. The highest investment round they participated in was $1.4B. Among their most notable exits are Intellia Therapeutics and Novartis. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.